BioLife Solutions, Inc., a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, launched a new line of high capacity-controlled rate freezers (HCRF), with an initial shipment to a leading cell therapy company. The freezer will be a critical component in this customer’s cold chain management of several allogeneic cell therapies in development.
Todd Berard, Chief Marketing Officer, BioLife, said: “This product launch expands our Cryogenic Freezer Platform with high capacity-controlled rate freezers designed specifically to meet the needs of cell and gene therapy developers. We’re very pleased to support this and several other pending customers by providing a critical cold chain management platform to protect their high-value biologic materials that require precise control of the critical freezing process and subsequent frozen storage.”
HCRF product line features large volume freezing, quality assurance data management, touch screen controller, multiple fans and probe design, precision control and innovative racking systems, reducing operational cost.
Roderick de Greef, Chief Financial and Operating Officer, BioLife Solutions, said: “The team at CBS has worked hard to complete the design, manufacturing and validation of this new and differentiated controlled rate freezer. We have said that new product introductions are key to driving gross margin expansion within our freezer line and, this is a step toward that goal. We expect unit gross margins on this product family in the mid to high 50% range, with average selling prices in the $450,000 to $750,000 range.”